Transdermal Nicotine Treatment and Progression of Early Parkinson’s Disease
Authors:
- 22 August 2023
- journal article
- research article
- Published by Massachusetts Medical Society in NEJM Evidence
- Vol. 2 (9)
Abstract
Nicotine Treatment and Parkinson's DiseaseIn this randomized, controlled trial, patients with Parkinson's disease not on dopaminergic therapy were randomly assigned to receive transdermal nicotine or placebo. After 1 year, there was no difference in the change in Total Unified Parkinson's Disease Rating Scale score between groups.Keywords
This publication has 33 references indexed in Scilit:
- Reward, Addiction, Withdrawal to NicotineAnnual Review of Neuroscience, 2011
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's DiseaseNew England Journal of Medicine, 2009
- Explanatory and Pragmatic Attitudes in Therapeutical TrialsJournal of Clinical Epidemiology, 2009
- Nicotine and Parkinson's disease: Implications for therapyMovement Disorders, 2008
- Physiology and immunology of the cholinergic antiinflammatory pathwayJournal of Clinical Investigation, 2007
- Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primatesJournal of Neurochemistry, 2006
- Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivinProceedings of the National Academy of Sciences, 2006
- Smoking and Parkinson's disease: Systematic review of prospective studiesMovement Disorders, 2004
- Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammationNature, 2002
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992